Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2025.17676
Abstract: Key Points Question Is paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) safe and associated with equivalent outcomes as cisplatin-based HIPEC in the treatment of advanced ovarian cancer after interval cytoreductive surgery? Findings In this cohort study with… read more here.
Keywords: paclitaxel based; based hipec; advanced ovarian; ovarian cancer ... See more keywords
Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Hyperthermia"
DOI: 10.1080/02656736.2024.2304250
Abstract: Abstract Purpose Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney… read more here.
Keywords: cisplatin based; based hipec; risk; risk factors ... See more keywords
Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers15010165
Abstract: Simple Summary Colorectal peritoneal metastases could potentially benefit from locoregional treatments such as cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Three recently published RCTs that have investigated HIPEC in the setting of radical or prophylactic/II^… read more here.
Keywords: prophylochip colopec; peritoneal metastases; based hipec; hipec ... See more keywords